NO941383L - Stabilisering av humant interferon - Google Patents

Stabilisering av humant interferon

Info

Publication number
NO941383L
NO941383L NO941383A NO941383A NO941383L NO 941383 L NO941383 L NO 941383L NO 941383 A NO941383 A NO 941383A NO 941383 A NO941383 A NO 941383A NO 941383 L NO941383 L NO 941383L
Authority
NO
Norway
Prior art keywords
stabilizers
human interferon
stabilization
interferon
storage stability
Prior art date
Application number
NO941383A
Other languages
English (en)
Other versions
NO941383D0 (no
Inventor
Ii William E Stewart
Original Assignee
Dallas Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dallas Biotherapeutics Inc filed Critical Dallas Biotherapeutics Inc
Publication of NO941383D0 publication Critical patent/NO941383D0/no
Publication of NO941383L publication Critical patent/NO941383L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Preparater for stabilisering av humant interferon, inkludert farmasøyt- iske preparater for topiske anvend- elser. Aminstabiliseringsmidler, slik som primære alifatiske aminer, og anioniske stabiliseringsmidler, slik som litium-organosutfater, beskytter humane interferoner mot nedbrytning og tilveiebringer forhøyet lagringsstabi- litet. Disse stabiliseringsmidler inne- holdende interferon kan tilsettes til egnede farmasøytiske bærere for topiske anvendelser. De topiske produkter opp- viser også forhøyet lagringsstabilitet.
NO941383A 1991-11-08 1994-04-15 Stabilisering av humant interferon NO941383L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/790,670 US5236707A (en) 1991-11-08 1991-11-08 Stabilization of human interferon
PCT/US1992/008292 WO1993008832A1 (en) 1991-11-08 1992-09-30 Stabilization of human interferon

Publications (2)

Publication Number Publication Date
NO941383D0 NO941383D0 (no) 1994-04-15
NO941383L true NO941383L (no) 1994-06-29

Family

ID=25151414

Family Applications (1)

Application Number Title Priority Date Filing Date
NO941383A NO941383L (no) 1991-11-08 1994-04-15 Stabilisering av humant interferon

Country Status (10)

Country Link
US (2) US5236707A (no)
EP (1) EP0611305A1 (no)
JP (1) JPH07500834A (no)
AU (1) AU664717B2 (no)
CA (1) CA2120944A1 (no)
FI (1) FI942017A0 (no)
MX (1) MX9206399A (no)
NO (1) NO941383L (no)
TW (1) TW215902B (no)
WO (1) WO1993008832A1 (no)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5904935A (en) * 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
CN1100565C (zh) * 1997-07-21 2003-02-05 合肥兆峰科大药业有限公司 干扰素软膏及其制备方法
US6192887B1 (en) * 1998-05-19 2001-02-27 The Pennsylvania State University Broad spectrum microbicidal and spermicidal compositions and methods having activity against sexually transmitted agents including papillomaviruses
AU6390299A (en) * 1998-09-29 2000-04-17 W. Robert Fleischmann Methods of treating diseased cells
JP2002532547A (ja) * 1998-12-22 2002-10-02 パナシーア ファーマスーティカルズ エルエルシー 皮膚の病変の治療
ES2196918T3 (es) * 1998-12-31 2003-12-16 Alza Corp Sistema de suministro osmotico dotado de piston con economia de espacio..
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
AU2587002A (en) 2000-11-03 2002-05-15 Biomedicines Inc Method for short-term and long-term drug dosimetry
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
ES2532906T5 (es) 2002-10-25 2022-03-23 Foamix Pharmaceuticals Ltd Espuma cosmética y farmacéutica
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8642564B2 (en) * 2004-08-25 2014-02-04 Aegis Therapeutics, Llc Compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US20060046969A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Antibacterial compositions for drug administration
WO2006025882A2 (en) * 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US9114069B2 (en) * 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
CU23432B6 (es) 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
AU2007266475B2 (en) 2006-05-30 2009-12-03 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
DK2049081T3 (da) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelarrangementer
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
PT2157967E (pt) 2007-04-23 2013-04-03 Intarcia Therapeutics Inc Formulações de suspensões de péptidos insulinotrópicos e suas utilizações
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
EP2242476A2 (en) 2008-01-14 2010-10-27 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
US20090258865A1 (en) * 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
CA2760186C (en) 2009-04-28 2019-10-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
KR102148624B1 (ko) 2009-09-28 2020-08-26 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
US8871184B2 (en) 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US8174881B2 (en) 2009-11-24 2012-05-08 Micron Technology, Inc. Techniques for reducing disturbance in a semiconductor device
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
PT3415139T (pt) 2011-06-14 2022-06-20 Neurelis Inc Administração de benzodiazepina
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR20240042548A (ko) 2015-06-03 2024-04-02 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CA2978573A1 (en) 2016-09-08 2018-03-08 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7404589A (nl) * 1974-04-03 1975-10-07 Stichting Rega V Z W Werkwijze voor het stabiliseren van interferon.
NL7404590A (nl) * 1974-04-03 1975-10-07 Stichting Rega V Z W Werkwijze voor het reactiveren van interferon.
US4503035B1 (en) * 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
US4462985A (en) * 1980-08-22 1984-07-31 University Of Illinois Foundation Delivery of biologically active components of heterologous species interferon isolates
EP0305551A3 (en) * 1981-10-13 1990-01-10 Exovir, Inc. Pharmaceutical compositions for topical application
EP0080879B1 (en) * 1981-11-28 1986-10-01 Sunstar Kabushiki Kaisha Pharmaceutical composition containing interferon in stable state
EP0082481B2 (en) * 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
US4957734A (en) * 1982-06-14 1990-09-18 Exovir, Inc. Treatment of certain skin malignancies and pre-malignant skin lesions, herpes zoster and psoriasis
US4462986A (en) * 1982-11-04 1984-07-31 Ens Bio Logicals, Inc. Synergistic anti-herpes compositions
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
US5165921A (en) * 1989-01-23 1992-11-24 National Geno Sciences, Inc. Method for treating condyloma acuminatum with interferon
US5326892A (en) * 1992-11-24 1994-07-05 Advanced Technology Materials, Inc. Bimetallic alkoxide reagents and method of making the same

Also Published As

Publication number Publication date
FI942017A (fi) 1994-05-02
US5431909A (en) 1995-07-11
TW215902B (no) 1993-11-11
JPH07500834A (ja) 1995-01-26
WO1993008832A1 (en) 1993-05-13
EP0611305A1 (en) 1994-08-24
FI942017A0 (fi) 1994-05-02
CA2120944A1 (en) 1993-05-13
AU2788892A (en) 1993-06-07
US5236707A (en) 1993-08-17
AU664717B2 (en) 1995-11-30
NO941383D0 (no) 1994-04-15
MX9206399A (es) 1993-08-01

Similar Documents

Publication Publication Date Title
NO941383L (no) Stabilisering av humant interferon
EP0564739A3 (no)
NO934706D0 (no) Substituerte 4-fenyl-pyridoner og 4-fenyl-2-alkoksypyridiner
ATE73657T1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eubnes arzneimittels zur behandlung von endometriose.
CS145091A3 (en) Isoxazole-4-carboxamides and amides of hydroxyalkylidene cyanacetic acid, medicaments comprising said compounds and their application
DE3686483D1 (de) Arzneimittel.
NO870441D0 (no) Farmasoeytiske preparatformer for stabilisering av alfa- interferon.
NO306403B1 (no) Nye sulfonamidopyrimidiner, anvendelse av dem og farmasöytiske preparater inneholdende dem
ATE106860T1 (de) R-enantiomer von n-propargyl-1-aminoindan, dessen herstellung und dieses enthaltende pharmazeutische zusammensetzungen.
NO954544D0 (no) Stabile flytende preparater av gamma-interferon
NO923721D0 (no) 4-desoksy-4-epipodophyllotoxin-derivat eller farmasoeytiskakseptabelt salt derav
DE68903092D1 (de) Laktamimide in der behandlung arzneiresistenter protozoeninjektionen.
DE3773017D1 (de) Nicorandil enthaltende zubereitung zum einspritzen.
DE3381378D1 (de) Derivate von aminosaeuren und antihypertensive arzneimittel diese enthaltend.
FI853648L (fi) Foerfarande foer framstaellning av farmaceutiskt aktiva 4,5-dihydro-4-okso-2-/(2-trans-fenylcyklopropyl) amino/-3-furankarboxylsyror och derivat daerav.
ATE172721T1 (de) Aminosäurederivate und ihre verwendung als enkephalinase-inhibitoren
DK0533408T3 (da) Kosmetik og farmaceutika indeholdende extensiner
NO881308D0 (no) Dihydropyridinamider, fremgangsmaate til deres fremstilling og deres anvendelse i legemidler.
DK605589A (da) Anvendelse af aminobenzocycloalkaner eller syreadditionssalte deraf til fremstilling af et farmaceutikum, saaledes fremstillet praeparat og dettes anvendelse
ES2118248T3 (es) Esteres y amidas de 9-cloro-prostaglandina y su empleo para preparar medicamentos.
ES2095431T3 (es) N-(isoquinolein-5-il)-sulfonil-azacicloalcanos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
NO306468B1 (no) Nye fosfolipid-derivater, deres fremstilling, legemiddel inneholdende derivatene og derivatenes anvendelse
IT9048066A0 (it) 2- amminotetraline-6, 7-sostituite attive come immunomodulanti e composizioni farmaceutiche che le contengono.
DK430789A (da) Laegemiddel indeholdende fytosteroler eller derivater deraf med forbedret vanoploeselighed
ATE210632T1 (de) Pestizide